-
Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use
Tuesday, December 12, 2017 - 11:12am | 405Read More...Omeros Corporation (NASDAQ: OMER) shares are trading higher Tuesday after the commercial-stage biopharma company announced FDA approval for its supplemental new drug application, or sNDA, for OMIDRIA, which expands the indication to include use in pediatric patients, from birth through 17 years...
-
Cantor Fitzgerald's Piros Still Isn't A Buyer Of Omeros After Tuesday's FDA Win
Tuesday, June 13, 2017 - 1:20pm | 340Read More...Shares of Omeros Corporation (NASDAQ: OMER) soared higher by more than 15 percent on Tuesday after the U.S. Food and Drug Administration granted a breakthrough therapy designation to the company's treatment of Immunoglobulin A nephropathy called OMS721. The FDA's designation provides Omeros with...
-
Wedbush Reduces Fair Value Estimate on Omeros to $11 (OMER)
Friday, April 1, 2011 - 8:16am | 130Read More...Wedbush is out with its report today on Omeros (NASDAQ: OMER), lowering its fair value estimate from $18 to $11. In a note to clients, Wedbush writes, "We believe that OMER is still at an attractive valuation even though we decreased our fair value to about $11 from $18. Omeros is not a one-trick...
-
Deutsche Bank Downgrading Omeros To Hold
Friday, April 1, 2011 - 8:06am | 101Read More...According to Deutsche Bank, Omeros (NASDAQ: OMER) is downgraded to Hold post negative OMS103 Ph3 data. Deutsche Bank reported that it is downgrading Omeros shares to HOLD, following the announcement of negative Ph 3 results for OMS103HP, the co's lead product candidate for improving outcomes in...
-
Wedbush Lowers PT On Omeros To $11
Friday, April 1, 2011 - 7:43am | 19Read More...Wedbush Securities has lowered the price target on Omeros Corporation (NASDAQ: OMER) from $18 to $11 and maintains its Outperform rating.
-
Deutsche Bank Downgrades Omeros To Hold, PT To $6
Friday, April 1, 2011 - 7:30am | 19Read More...Deutsche Bank has downgraded Omeros (NASDAQ: OMER) from Buy to Hold and has lowered the price target from $13 to $6.
-
Deutsche Bank Reports Positive Surgery Data From Omeros
Thursday, March 24, 2011 - 7:51am | 126Read More...Deutsche Bank has issued a report on the positive results from the Ph 2b trial of OMS302 from Omeros (NASDAQ: OMER). According to the report, "We are encouraged by the positive cataract surgery study results and the success of Omeros' PharmacoSurgery programs to date. Importantly, we continue to...
